Enrico De Toni retweeted
Read our paper in @JHEP_Reports on the risk of bleeding and thromboembolism in atezobev vs lenvatinib for HCC. Big thanks to the fantastic collaborators!
🩸 As treatment with atezolizumab/bevacizumab and lenvatinib for HCC may cause an increased risk of bleeding, a study by @N_BenKhaled and colleagues analyzed the efficacy and safety of each treatment in a real-world population.
Learn more: buff.ly/4aSN9Ym
#LiverCancer
One has to concentrate on key cunning questions with immediate clinical relevance until more data are available. Bravi, Najib and Florian!
Read our paper in @JHEP_Reports on the risk of bleeding and thromboembolism in atezobev vs lenvatinib for HCC. Big thanks to the fantastic collaborators!
Enrico De Toni retweeted
Happy Jean Sibelius Day and Day of #Finnish Music 💙 Today, we celebrate Finnish music – and there is no better way to do so than by listening to Sibelius' Finlandia. 🎞️ © ONEVIOLIN, @iamoneviolin
Enrico De Toni retweeted
Liver cancer awareness month
Join us in place or through zoom for the next HPB café
📄: Novel strategies & systemic therapy for HCC
📣: Pr E.N De Toni
📅: 15 Oct @ 14:00 (GMT +4)
🔗: us06web.zoom.us/meeting/regi…
@sqcccrc
@IHPBA
@ESSOnews
@ProfPanaro
@EnricoNDeToni
Enrico De Toni retweeted
#GUTFrontCover The beautiful New Town Hall & St. Mary's Column at the Marienplatz in Munich, Germany. Read in this issue the consensus paper on the definition of sludge & microlithiasis as a possible cause of pancreatitis via bit.ly/46yZXRF
@JuliaMayerle @LMU_Muenchen
Enrico De Toni retweeted
🤔 Curious about the population-level impact of changes in HCC systemic therapies on clinical practice and healthcare costs? 🏥💰 Check out our latest article for insights @OncologyAdvance European Journal of Cancer📚
@OncoAlert #livertwitter
authors.elsevier.com/a/1hiNx…
Enrico De Toni retweeted
4-yr OS update from the phs 3 HIMALAYA trial of tremelimumab + durvalumab in HCC at #WCGIC2023
👉Excellent long-term survival data for STRIDE
👉4-yr OS rate of 19% (unprecedented in HCC)
👉Long-term OS observed in relevant subgroups, incl. pts with non-viral liver disease
@myESMO @EASLnews @ILCAnews #livertwitter @WCGIC
🎉 Congrats Florian Reiter on the outstanding presentation of thromboembolic event data for Atezo/Bev or Lenvatinib in HCC patients! Long-awaited and clinically relevant information. 👏 Best of luck with future data collection and analysis.
Enrico De Toni retweeted
Happy to share our experience using Ustekinumab for refractory immunotherapy colitis with #MimiWang @MDAndersonNews
@MSKCancerCenter @AmJGastro
✅ 19 pts refractory to steroids + infliximab and/or vedolizumab
✅ 68% achieved clinical remission w UST
journals.lww.com/ajg/Abstrac…
Enrico De Toni retweeted
Got a reviewer commenting that my writing should be proofread by a native English speaker. I hope this reply I’m drafting isn’t too much! 😬
Enrico De Toni retweeted
Great to reconnect with the one and only Yinghong Wang @DDWMeeting. We’re grateful for the expertise she shared during her talk #UEG2022. Her new book on ICI toxicity is a must-read! @my_ueg #ddw2023
Enrico De Toni retweeted
Thrilled to announce that the Phase II MONTBLANC trial has enrolled its first patient at @LMU_Uniklinikum. This trial is the first to evaluate durvalumab, tremelimumab, bevacizumab triplet in advanced HCC. More sites to come in Germany and Italy. @EnricoNDeToni @lorenzarimassa